T he deoxycorticosterone acetate (DOCA)-salt model of hypertension is a widely used animal model of mineralocorticoid and salt-sensitive hypertension characterized by elevated brain Angiotensin (Ang)-II levels without changes in peripheral Ang-II levels.
T he deoxycorticosterone acetate (DOCA)-salt model of hypertension is a widely used animal model of mineralocorticoid and salt-sensitive hypertension characterized by elevated brain Angiotensin (Ang)-II levels without changes in peripheral Ang-II levels. 1, 2 There is abundant evidence that DOCA-salt hypertension is mediated by increased oxidative stress. Oxidative stress involves an increased production of reactive oxygen species (ROS) or decreased antioxidant enzymes to metabolize them. Ang-II, the major actor of the renin-angiotensin system (RAS), stimulates the production of ROS. Previous evidence has shown the importance of the brain RAS in the regulation of blood pressure (BP) and in the development of hypertension. 3 Accumulating evidence indicate that ROS are involved in mediating many of the effects of Ang-II, including autonomic dysfunction and sympatho-excitation, leading to neurogenic hypertension. [4] [5] [6] In the last decade, angiotensin-converting enzyme 2 (ACE2) has emerged as a key player in compensatory mechanisms opposing the overactive RAS, a main contributor to the development of several cardiovascular diseases, including hypertension. It has been previously shown that Ang-II stimulation of Ang-II type 1 receptors (AT 1 R) induces ROS formation 4, 5, 7 and reduces ACE2 activity and expression in the brain and at the periphery. 8 Moreover, various genetic 9 and experimental 2,10-12 models of hypertension are associated with elevated proinflammatory cytokines and chemokines in the hypothalamic paraventricular nucleus (PVN), an important cardiovascular regulatory center in the brain. Our group 2, 7, 10, 13, 14 and others 15 have shown that overexpression of ACE2 in the brain, or specifically within the PVN, results in attenuation of BP in Ang-II-induced and
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DOCA-salt-induced neurogenic hypertension models. In DOCA-salt hypertension, ACE2 activity was reduced by 50% in the hypothalamus, whereas transgenic mice with ACE2 overexpression had a 2-fold increase in ACE2 activity, which was able to attenuate DOCA-salt hypertension. 2 However, the precise mechanisms by which increased brain RAS activity triggers hypertension and how ACE2 counteracts hypertension are unknown.
Cyclooxygenase (COX)-derived prostanoids are generated by either the constitutive isoform COX-1 or by the inducible form COX-2 and are implicated in BP regulation. 16, 17 Both COX isoforms are expressed in the brain and by acting as key rate limiting enzymes, contribute substantially to the generation of prostaglandins. 16, 17 Recent studies suggest a more diverse role for the prostanoid system components because both prohypertensive and antihypertensive roles coexist, affecting kidneys, blood vessels, endocrine organs, and the brain. [17] [18] [19] [20] Use of COX inhibitors and COX knockout mice resulted in contrasting results about the role of COX-1 and COX-2 in BP regulation. [17] [18] [19] [20] Increasing evidence suggests that considerable cross-talk between COX isoforms and nitric oxide (NO) and that modulation of both pathways affects the outcome of a physiological or pathological response. 21, 22 Although our group previously reported the participation of NO in the ACE2-mediated attenuation of neurogenic hypertension, 7, 13 the effect on COX expression remains to be elucidated. We hypothesized that the attenuation of inflammation and hypertension by ACE2 overexpression is regulated by COX-mediated signaling mechanisms in the brain. Therefore, in this study, we investigated the roles of oxidative stress, COX-isoforms, and the signaling mechanisms involved in the beneficial effects of brain ACE2 overexpression in neurogenic hypertension. Using a mouse model of DOCA-salt hypertension, and transgenic mice with neuron-targeted overexpression of ACE2, we examined whether oxidative stress and COX-isoforms in the brain contribute to the development of hypertension and whether ACE2 overexpression modulates these pathways in hypertension.
Methods
A detailed Methods section is available in the online-only Data Supplement.
Experimental Animals
Experiments were performed in adult male (14-16 weeks old; 25-30 g) transgenic syn-hACE2 (SA) mice and nontransgenic (NT) littermates. SA mice were generated in collaboration with Dr Curt D. Sigmund at The University of Iowa and back-crossed into the C57Bl/6 background for >9 generations. Animals were housed in a temperature-and humidity-controlled facility under a 12-hour dark/light cycle, fed standard mouse chow and water ad libitum. All procedures were approved by the LSU Health Sciences Center-NO Animal Care and Use Committee and are in agreement with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Experimental Design
SA and NT mice first underwent uninephrectomy <2.5% isoflurane anesthesia with oxygen flow (1 L/min). After 1 week of recovery, telemetry probes were implanted for conscious BP monitoring as described previously. 2, 13 A week later, baseline BP was recorded for 3 days. Mice were then randomly divided into 4 groups (n=12/group) and implanted subcutaneously either with a DOCA-silicone sheet (DOCA:silicone =1:3; DOCA 1 mg/g body weight) or with an empty silicone sheet. The mice receiving DOCA were switched to 1% NaCl in the drinking water. BP was continuously recorded for 3 additional weeks. In another set of experiments, uninephrectomized NT mice were infused intracerebroventricularly for 3 weeks, with COX-1 or COX-2 siRNA (GE Healthcare Dharmacon RNAi; 0.1 nmol/d) or artificial cerebrospinal fluid (n=6/group) while receiving DOCA-salt. At the end of the protocol mice were euthanized, the brains were collected and stored at −80°C until used.
Results
ACE2 Overexpression Prevents Oxidative Stress and Improves Antioxidant Enzyme Levels in the PVN
As we previously reported, 2 DOCA-salt treatment for 3 weeks resulted in increased mean arterial pressure, systolic and diastolic BP in NT mice, which were blunted in SA mice, confirming that brain ACE2 overexpression attenuates DOCAsalt-induced hypertension (Table) . Also, DOCA-salt hypertension was associated with similar increases in fluid intake and urinary excretion in both genotypes (Table) , suggesting that differences observed between NT and SA mice are unrelated to these parameters. Previous studies have shown that DOCA-salt hypertension is associated with increased oxidative stress. [23] [24] [25] To test whether ACE2 overexpression affects oxidative stress in neurogenic hypertension, protein expression of nicotinamide adenine dinucleotide phosphate-oxidase catalytic subunits (Nox-2 and Nox-4) and nitrotyrosine were assessed in the hypothalamic PVN using Western blotting. PVN was chosen because it is one of the pivotal brain regions integrating neuronal signals and sympathetic outflow in central BP regulation. In addition, we previously reported that ACE2 is present in this region and capable of modulating hypertension and cardiovascular function. 7, 10 DOCA-salt treatment caused a significant increase in PVN Nox-2 (+61±5%; P<0.001 versus NT+Sham) and Nox-4 (+50±13%; P<0.05 versus NT+Sham) expression in NT mice ( Figure 1A and 1B) . This response was attenuated in SA+DOCA mice. Furthermore, nitrotyrosine, a marker of ONOO − and an indicator of nitrosative stress, was significantly increased by DOCA-salt in NT mice Figure 1C ). DOCA-salt hypertension was associated with significant and similar (≈30%) decreases in catalase ( Figure 1D ) and total superoxide dismutase ( Figure 1E ) activities in the hypothalamus of NT mice (P<0.05 versus NT+Sham). However, the reduction of manganese superoxide dismutase activity was more pronounced with ≈70% being eliminated (P<0.05 versus NT+Sham; Figure 1F ). ACE2 overexpression had no effect on baseline catalase activity, but prevented the DOCA-salt-induced decrease in catalase activity in the hypothalamus ( Figure 1D ). At baseline, both superoxide dismutase and manganese superoxide dismutase levels were significantly higher in SA mice when compared with corresponding NT control mice. ACE2 overexpression dramatically prevented the DOCA-salt-mediated reduction in manganese superoxide dismutase activity ( Figure 1F ; P<0.05 for interaction between DOCA treatment and genotype).
ACE2 Overexpression Attenuates DOCA-SaltInduced Decreases in NOS Expression
To determine the effect of ACE2 overexpression on NO signaling, we measured expression of nitric oxide synthase (NOS) isoforms in the PVN using Western blot analysis. DOCA-salt treatment significantly decreased phosphorylated endothelial nitric oxide synthase and total endothelial nitric oxide synthase expression in the PVN of both NT and SA mice, but this decrease was significantly lower in SA mice (Figure 2A and 2B; P<0.05 for interaction between DOCA treatment and genotype). At baseline, neuronal nitric oxide synthase protein levels were significantly higher in SA mice when compared with corresponding NT control mice ( Figure 2C ). Furthermore, the importance of ACE2 for activation/reinforcement of NO-dependent pathways was illustrated by baseline upregulation of neuronal nitric oxide synthase expression (+30%; P<0.05 versus NT+Sham) in SA mice. Three weeks of DOCA-salt treatment resulted in decreased expression of neuronal nitric oxide synthase in NT mice (−26%; P<0.05 versus NT+Sham), which was prevented by overexpression of ACE2 in SA mice ( Figure 2C ; P<0.01 for SA+DOCA versus NT+DOCA). These results further confirm that ACE2 overexpression reinforces NO signaling within the brain thus attenuating neurogenic hypertension.
Brain ACE2 Overexpression Prevents DOCA Salt-Induced Increase in Akt and ERK1/2 Phosphorylation
Because mitogen-activated protein kinases (MAPK) and extracellular signal-regulated kinase 1/2 (ERK1/2) signal transduction pathways are involved in the pathogenesis of DOCA-salt hypertension 26 and coupled with MasR activation, 27 we evaluated the phosphorylation of protein kinase B (Akt) and ERK1/2 in the brain. Previous studies showed that Ang-II-mediated increase in ROS production leads to activation of p38 MAPK, which regulates the phosphorylation of Akt on Ser 473 . 28 Therefore, we measured the phosphorylation of Akt on Ser 473 in the PVN. As shown in Figure 2D , phosphorylation of Akt in the PVN was significantly increased in NT+DOCA mice, which was prevented in SA+DOCA animals. Phosphorylation at residues No differences in total ERK1/2 protein levels in the PVN were observed among the groups ( Figure 2E ). However, phosphorylation of ERK1/2 at Thr 202 /Tyr 204 was increased in the PVN from NT+DOCA mice, but not in SA+DOCA group. These results suggest that Akt and ERK1/2 signaling pathways are targeted by ACE2 counter regulation during DOCA-salt hypertension.
ACE2 Overexpression Attenuates DOCA-SaltInduced Increase in COX Expression
The COX-derived prostanoids, generated by either the largely constitutive isoform COX-1 or by the inducible form COX-2, have long been implicated in the pathogenesis of Ang-II-induced hypertension, although their precise role is unclear. 19, 29, 30 Accordingly, we sought to determine the expression of PVN COX isoforms in DOCA-salt hypertension and whether ACE2 has any modulatory effect. In NT mice, DOCA-salt treatment resulted in a 2.5-fold increase in COX-1 and a 5-fold increase in COX-2 mRNA expression in the PVN (Figure 3A and 3B; P<0.05 versus NT+Sham). However, this increase was attenuated in SA+DOCA mice. Furthermore, DOCA-salt treatment increased COX-1 and COX-2 protein expression in both NT and SA mice (Figure 3C and 3D ; P<0.05 versus NT+Sham), but this increase tended to be significantly lower in SA mice (P<0.05 versus NT+DOCA; P<0.05 for interaction between DOCA treatment and genotype). Together, these data suggest that both COX-1 and COX-2 expression is increased in DOCAsalt hypertension and ACE2 exerts an inhibitory effect on COX expression.
Brain ACE2 Overexpression Prevents DOCA-SaltInduced Changes in EP Receptor Expression
The COX-derived major prostanoids prostaglandin E2 via acting on 4 G protein-coupled receptors (EP1 through EP4), participates in the mechanisms of hypertension and related complications. 16, 18, 30 To determine the specific receptors involved, mRNA expression was assessed in the PVN. DOCAsalt hypertension was associated with significant increase in EP1, EP3, and decrease in EP4 receptors mRNA expression in NT+DOCA mice ( Figure S1 in the online-only Data Supplement). DOCA-salt hypertension did not affect mRNA expression of EP2 receptor in any of the groups. ACE2 overexpression had no effect on these receptors mRNA at baseline. However, ACE2 expression in the brain reversed the DOCAsalt-induced upregulation of these receptors expression.
Brain-Targeted Inhibition of COX-1 or COX-2 Attenuates DOCA-Salt Hypertension
Because our data show that, both COX-1 and COX-2 mRNA and protein were significantly increased in PVN, we further investigated whether COX-1 or COX-2 contribute to the development of DOCA-salt hypertension using siRNA. To validate our gene silencing approach, we first validated the specificity of COX-1 and COX-2 siRNA in Neuro2A cells ( Figure S2 Because microglia in the PVN is activated and release inflammatory cytokines during hypertension, 12 we determined PVN microglial activation using immunostaining, and inflammatory cytokine gene expression using real-time reverse transcription polymerase chain reaction. DOCA-salt hypertension resulted in microglial activation in the PVN, as indicated by increased specific microglial marker Iba-1 immunofluorescence staining (retracted processes, enlarged perikarya, and concentrated staining; Figure 5A ) and increased Iba-1 protein expression ( Figure 5B ) in NT+DOCA group, which was prevented by either COX-1 or COX-2 gene silencing. DOCAsalt hypertension also increased PVN mRNA expression of proinflammatory cytokines tumor necrosis factor, IL-1β, and IL-6, which was attenuated by either COX-1 or COX-2 gene silencing ( Figure 5C-5E) . Furthermore, assessment of COX-1 and COX-2 immunoreactivity in the PVN revealed enhanced COX-1 ( Figure S3 ) and COX-2 ( Figure S4 ) protein expression in the PVN of NT+DOCA group mice. COX-1 immunoreactivity was more prominent in neurons (colocalization with NeuN) while whereas COX-2 was expressed in both neurons and non-neuronal cells. The size and shape of these latter cells point to astrocytes, including those located in the proximity of blood vessels. Blockade of COX using siRNA infusion resulted in the reduction of COX-1 and COX-2 immunoreactivity in all cell types within the PVN after DOCA-salt treatment. These findings along with reduced inflammation and microglial activation by COX knockdown suggest that COX expression in the hypothalamic PVN plays an important role in the induction of neuroinflammation and progression of DOCA-salt hypertension.
Discussion
Our laboratory previously reported that overexpression of ACE2 in the brain blunts the development of Ang-II-induced hypertension 10, 13 and DOCA-salt hypertension. 2 Yet, the signaling mechanisms are still elusive. In this study, we show that DOCA-salt hypertension was associated with increased oxidative stress and decreased NOS expression, which was attenuated by brain-specific ACE2 overexpression. In addition, ACE2 overexpression resulted in decreased phosphorylation of Akt and ERK1/2, which was increased by DOCA-salt hypertension. Importantly, DOCA-salt hypertension resulted in increased COX-1 and COX-2 expression in the hypothalamic PVN, which was blunted by ACE2 overexpression. Furthermore, gene silencing of COX-1 and COX-2 specifically in the brain attenuated microglial activation and accompanied neuroinflammation, blunted phosphorylation of Akt and ERK1/2, ultimately reducing DOCA-salt hypertension. Taken together, these results coupled with our previous studies suggest that brain-targeted ACE2 overexpression prevents DOCA-salt hypertension by modulating NOS and ERK1/2 DOCA-salt hypertension was not significantly altered in mice treated with the ROS scavenger tempol or losartan systemically for 3 weeks and there was no difference in plasma cytokine levels. However, other studies have shown that treatments with tempol 6 or apocynin, 32 an nicotinamide adenine dinucleotide phosphate-oxidase inhibitor, attenuate DOCA-salt hypertension. We recently reported that DOCA-salt hypertension was associated with increased expression of proinflammatory cytokines in the hypothalamic PVN and ACE2 overexpression in the brain attenuated this inflammatory response. 2 Also, central infusion of losartan blunted the DOCA-salt-induced increase in BP. 2 In this study, catalase, superoxide dismutase, and manganese superoxide dismutase activities in the hypothalamus were reduced in DOCA-salt-treated mice compared with normotensive controls, suggesting that defense mechanisms against oxidative stress are decreased in hypertensive mice. This was associated with increased oxidative stress as indicated by increased Nox-2, Nox-4 and nitrotyrosine levels and decreased NOS expression and phosphorylation in the PVN. However, ACE2 overexpression in the brain improved the antioxidant enzyme activities and decreased oxidative stress suggesting that the beneficial effects of ACE2 overexpression might be mediated by reduction in oxidative stress. In addition, we showed previously that overexpression of ACE2, which cleaves Ang-II to Ang-(1-7), in the brain prevents the development of hypertension induced by peripheral Ang-II infusion by, at least partly, increasing NOS and NO production.
13,34 Thus ACE2 overexpression not only decreases Ang-II-mediated oxidative stress but also improves NO antioxidant mechanisms likely by Ang-(1-7) formation. Ang-II acting through AT 1 R can trigger signaling cascades that stimulate MAPKs, including ERK1/2. [35] [36] [37] It has been shown that male DOCA rats displayed more severe hypertension versus females, which was associated with over activation of ERK1/2 pathway in the vasculature. 38 Also, Akt phosphorylation is an important phenomenon in the signal transduction pathway activated by growth factors, including Ang-II. 38 In vitro studies using cultured rat vascular smooth muscle cells 8 or neuronal cells, 36 showed that MAP kinase and ERK1/2 pathways are involved in AT 1 R-mediated changes in ACE2 expression. In the present in vivo study, we show that ACE2 overexpression prevented the DOCA-salt-induced phosphorylation of both Akt and ERK1/2 in the PVN suggesting that the beneficial effects of ACE2 overexpression on hypertension are mediated by Akt and ERK1/2 signaling pathways.
A major finding in this study is that the DOCA-salt hypertension was associated with increased expression of COX-1 and COX-2 in the hypothalamic PVN of DOCA-salt-treated NT mice. ACE2 overexpression attenuated this increased COX expression, suggesting that ACE2 beneficial effects on DOCA-salt hypertension are in part mediated by downregulation of COX expression. Several studies suggest that COX products differentially modulate the pressor response in different models of hypertension. [18] [19] [20] 39, 40 Qi et al 20 previously showed that pharmacological blockade or genetic deletion of COX-1 but not COX-2 reduced the acute pressor effects 18 recently demonstrated that elevations in BP during slow pressor Ang-II infusions are abolished in mice with global null mutations of EP1R or COX-1 but not COX-2 and that COX-1-derived PGE2 signaling through EP1R in the subfornical organ is required for ROS-mediated hypertension induced by systemic infusion of Ang-II. However, it has been shown that BP response and superoxide production were significantly blunted in COX-2 knockout mice. 39 Furthermore, COX-2 inhibition by rofecoxib and nimesulide attenuated Ang-II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats. 29 In addition, in heart failure rats with chronic elevation of proinflammatory cytokines, COX-1 was not altered but COX-2 was increased in the PVN. 41 A recent study also suggests that systemic inflammation activates microglia in rostral ventrolateral medulla to induce COX-2-dependent neuroinflammation leading to an increase in oxidative stress that contributes to neurogenic hypertension. 42 Together, these studies highlight the importance of COX expression in the manifestation of a variety of disease conditions, including neurogenic hypertension. The reasons attributed to these variations included study design, experimental models, tissue specificity, sex of the animals, background of the transgenic mice, and selectivity of the COX inhibitors. In this study, we used a gene silencing approach to block COX isoforms specifically in the brain thus preventing developmental compensatory mechanisms often arising in knockout animals. Both COX-1 and COX-2 gene and protein expression significantly increased in the PVN during DOCAsalt hypertension, accompanied by increased microglia activation and inflammation. Moreover, our study highlighted the contribution of multiple cell types within the brain. Indeed, our data show that COX-1 immunoreactivity was more prominent in neurons while COX-2 was expressed in both neurons and non-neuronal cells, probably astrocytes. A study by Wang et al 43 demonstrated the colocalization of AT 1 R and COX-1 in subfornical organ neurons, and suggested that the possibility of cross-talk between COX-2/EP1R and NOX/ROS signaling in modulating Ang-II-induced hypertension. In our study, brain-targeted COX inhibition with siRNA resulted in reduced microglial activation, decreased inflammatory cytokine production, and attenuation of hypertension suggesting a role for both COX isoforms in the regulation of DOCA-salt hypertension. However, additional studies are needed to determine the relative contribution of COX-mediated signaling, and to identify the contribution of each cell type in these signaling events during the development of DOCA-salt hypertension.
It is important to note, however, that because of the infusion of COX siRNA intracerebroventricularly in this study, the COX inhibitory effects may have affected additional cardiovascular regulatory regions in the brain and elicited a similar response as in the PVN. Previous publications from our group highlighted the important role of ACE2 in the PVN in the regulation of hypertension.
2,7,10-12 PVN-specific overexpression of ACE2 using bilateral injection of hACE2-adenovirus attenuated Ang-II-induced hypertensive response in rats, 10 and reduced oxidative stress and normalized cardiac dysautonomia in ACE2 knockout mice. 7 We also showed that knockdown of ACE2 in the PVN partially reversed the protective effects of brain ACE2 in DOCA-salt hypertension, suggesting the involvement of other cardiovascular centers apart from PVN in the BP homeostasis. 44 Further studies will be required to determine the predominant central site or sites of action in COX-mediated inflammation in DOCA-salt hypertension.
In summary, we have provided evidence that DOCA-salt hypertension was associated with increased oxidative stress and decreased antioxidant enzyme activity in the brain and ACE2 overexpression prevents these changes. This beneficial effect of ACE2 seems to be mediated by reduction in activated Akt and ERK1/2-induced COX-1 and COX-2 expression in the brain. In addition, brain-targeted COX inhibition reduced microglia activation, decreased neuroinflammation, and attenuated DOCA-salt hypertension. As summarized schematically in Figure 6 , these findings collectively support important role for ACE2 and COX isoforms in the pathogenesis of DOCAsalt hypertension in the setting of increased brain oxidative stress and inflammation.
Perspectives
Although in the last decade ACE2 has emerged as a potential therapeutic target in a variety of cardiovascular diseases, the molecular and cellular mechanisms underlying these beneficial effects of ACE2 remain unknown. This study provides evidence that MAPK-mediated elevated COX-1 and COX-2 expression in the hypothalamic PVN region is key underlying mechanism responsible for the pathogenesis of DOCAsalt hypertension. Brain-specific ACE2 expression prevented DOCA-salt-induced oxidative stress, improved antioxidant and NOS signaling, blunted the MAPK activation and COX expression, thereby attenuating DOCA-salt hypertension. Furthermore, brain-targeted gene silencing of either COX-1 
Detailed Methods
Experimental Design
SA and NT mice first underwent uni-nephrectomy under 2.5% isoflurane anesthesia with oxygen flow (1 L/min). After 1 week of recovery, telemetry probes were implanted for conscious BP monitoring as described previously. 1, 2 A week later, baseline BP was recorded for 3 days. Mice were then randomly divided into 4 groups (n=12/group) and implanted subcutaneously either with a DOCA-silicone sheet (DOCA:silicone =1:3; DOCA 1 mg/g body weight) or an empty silicone sheet. The mice receiving DOCA were switched to 1% NaCl in the drinking water. BP was continuously recorded for 3 additional weeks. A subset of mice was placed into metabolic cages after 2 weeks of sham or DOCA-salt treatment and the fluid intake and urine output were measured. In another set of experiments, uni-nephrectomized NT mice were infused intracerebroventricularly (icv) for 3 weeks, with COX-1 or COX-2 siRNA (GE Healthcare Dharmacon RNAi; 0.1 nmoles/day) or artificial cerebrospinal fluid (aCSF) (n=6/group) while receiving DOCA-salt. At the end of the protocol mice were euthanized, the brains were collected and stored at -80°C until used.
Antioxidant Enzyme Bioassays
Catalase activity was measured in hypothalamus homogenates (100 µg of protein) using a commercially available Catalase Assay Kit (Cayman Chemicals, #707002) according to manufacturer's instructions. Catalase activity was expressed as nmol/min/mL. Superoxide dismutase (SOD) and MnSOD activity were measured in hypothalamus homogenates (100 µg of protein) using a SOD Assay Kit (Cayman Chemicals, #706002) according to manufacturer's instructions. MnSOD activity was measured by addition of 3 mM KCN to the assay to inhibit both Cu/ZnSOD and extracellular SOD, resulting in detection of only MnSOD activity. SOD activity was expressed as U/mL, where, one unit is defined as the amount of enzyme needed to exhibit 50% dismutation of the superoxide radical.
Western Blot Analysis
Micropunches of the paraventricular nucleus (PVN) were obtained from frozen brain sections (brain punch Ø1.0 mm, Stoelting). PVN protein extracts (10 µg) were processed for Western blotting as described previously 1, 3 using Nox-2 (BD Biosciences, #611415, 1:500), Nox-4 (Abcam, #ab109225, 1:1000), Nitrotyrosine (Meridian, #K97520G, 1:1000), phospho-eNOS (Ser1177, Cell Signaling, #9571, 1:1000), total eNOS (Cell Signaling, #9572, 1:1000), nNOS (Cell Signaling, #4234, 1:1000), Cox-1 (Abcam, #ab109025, 1:200), Cox-2 (Abcam, # 15191, 1:200), Iba-1 (Wako Chemicals, # 019-19741, 1:1000), phospho-Akt (Ser 473, Cell Signaling, #4058, 1:1000), total Akt (Cell Signaling, #9272, 1:1000), phospho ERK1/2 (Santa Cruz, #sc-7383, 1:1000), and total ERK1/2 (Cell Signaling, #9102, 1:1000) antibodies. Equal loading was determined using γ-tubulin (Sigma, #T5192, 1:5000) or α-Tubulin (Sigma, T6199, 1:5000) as a loading control.
Quantitative Real Time RT-PCR
Total RNA was isolated from PVN punches using RNeasy plus micro kit (Qiagen) and cDNA was synthesized using high capacity cDNA synthesis kit (Applied Biosystems). Real Time PCR amplification reactions were performed with SYBR Green Master mix (Roche) using a Real time PCR machine (Roche LightCycler 480). Data were normalized to β-actin expression by the 2 -(∆∆CT) comparative method.
Immunohistochemistry
Immuno-fluorescent detection of Iba-1, COX-1 and COX-2 was performed in the PVN of mice after 3 weeks of Sham or DOCA-salt treatment. Anaesthetized mice were perfused transcardially with PBS (0.1M, pH 7.4) for 2 min followed by 4% paraformaldehyde in PBS (0.1M, pH 7.4) for 10 min as described previously. 4 The brains were removed, post fixed for 2 hr in 4% paraformaldehyde in PBS (0.1M, pH 7.4) and then placed in 30% sucrose in PBS solution overnight. Free floating sections (30 μm, coronal) were incubated with a Cox-1 (Abcam, #ab109025, 1:200), Cox-2 (Abcam, # 15191, 1:200), and Iba-1 (Wako Chemicals, # 019-19741, 1:800) for 36 hours at 4 ºC. Sections were washed with PBS, incubated with appropriate Alexa flour conjugated secondary antibodies (Life Technologies, 1:200 dilution) for 2 hours at room temperature. Additionally, either or both primary and secondary antibodies were omitted in the incubation to check for unspecific staining. Images were captured using a laser confocal microscope.
Cell Culture Experiments
Neuro-2a cells (Mouse neuroblastoma, CCL-131, ATCC) and Neuro-2a cells were grown as described previously. 4, 5 For siRNA transfections, Neuro-2A cells were seeded (2×105 cells/well) in 6 well plates and after 24 hours transfected with COX-1 specific, COX-2 specific, and control siRNA using DharmaFECT transfection reagents (Thermo Scientific) according to the manufacturer's instructions. 1 After 48 hours of transfection, the cells were harvested for mRNA and protein analysis using real time RT-PCR and western blot, respectively.
Statistics
Data are presented as mean ±SEM. Data were analyzed by one-way ANOVA or two-way ANOVA followed by Bonferroni posthoc tests for multiple comparisons between means, as appropriate. Statistical comparisons were performed using Prism 5 (GraphPad Software). Differences were considered statistically significant at P<0.05. COX-2 expression is increased in the paraventricular nucleus during DOCA-salt hypertension. Mice brain sections exhibit immuno-reactivity for COX-2 (green), neurons (NeuN) and nuclei (DRAQ5). COX-2 expression was observed in both neuronal (cyan arrows) and non-neuronal (white arrows) cells during DOCA-salt hypertension. Both siRNA treatments normalized COX-2 immuno-reactivity, to pre-hypertension levels.
